Dr. Ghosh on the Potential Advantages of Frontline CAR T-Cell Therapy in DLBCL

Video

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma (DLBCL).

No biomarkers currently can inform whether a patient will respond to frontline chemoimmunotherapy. CAR T-cell therapy may provide a welcome alternative that can spare patients with DLBCL the toxicities associated with chemotherapy, Ghosh says. Moreover, patients could potentially obtain a long remission with a single infusion of CAR T-cell therapy vs multiple cycles of chemotherapy, Ghosh adds.

However, frontline treatment with traditional chemoimmunotherapy has demonstrated long-term remissions in around 60% of patients with DLBCL, says Ghosh. As such, demonstrating that CAR T-cell therapy is an effective frontline option could be difficult because the standard of care already elicits high response rates with potential curative benefit, Ghosh explains. Ultimately, a randomized clinical trial comparing chemoimmunotherapy with CAR T-cell therapy is warranted, concludes Ghosh.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.